Inovio Pharmaceuticals Q3 loss widens on warrant charge
INO•Inovio Pharmaceuticals reported a third-quarter net loss of $49.2 million, or $0.50 per share, including a $26.9 million non-cash loss from warrant liabilities. It raised $80.5 million in a public offering and expects to launch VOCERYQ commercially in the first quarter of 2027.
1. Quarterly results
Inovio Pharmaceuticals’ third-quarter net loss widened, driven mainly by a $26.9 million non-cash loss from the fair-value adjustment of warrant liabilities. Operating expenses were $19.8 million; research and development expenses fell while selling, general and administrative expenses rose ahead of the VOCERYQ launch.
2. Launch and cash outlook
The company raised $80.5 million in a public offering to support the launch. It expects a full commercial launch of VOCERYQ in the first quarter of 2027, plans to submit a European conditional marketing authorization application before the end of 2026, and estimates current cash will support operations into late 2027.
